Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LRAT | O95237 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23640180 | 1.00 | HSD17B10 (0.55) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL12454820 | 1.00 | HSD17B10 (0.55) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL19074567 | 1.00 | HSD17B10 (0.55) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL17879097 | 1.00 | HSD17B10 (0.55) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL17480019 | 1.00 | HSD17B10 (0.55) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL19337535 | 0.91 | MEN1 (0.52) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL12859458 | 0.91 | MEN1 (0.52) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL20067007 | 0.90 | MEN1 (0.46) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL13821014 | 0.90 | MEN1 (0.46) | HSD17B10TSHRMEN1LRATTRPV1 | |
| SCHEMBL26170073 | 0.90 | MEN1 (0.46) | HSD17B10TSHRMEN1LRATTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643509-B2 | Carbohydrate crosslinker | Galderma Holding SA (CH) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643509-B2 | Carbohydrate crosslinker | CD44, CSGALNACT1, STT3B | HSD17B10 1478/4885TSHR 1236/4885MEN1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.